Retatrutide is a peptide, not a steroid. It is a chain of amino acids joined by peptide bonds, carrying a fatty-acid modification, and it is built by peptide synthesis. A steroid belongs to a completely different chemical family, so the two are unrelated in structure,...
The glucagon in retatrutide refers to glucagon-receptor agonism, the third of the molecule's three receptor activities. Retatrutide is a triple agonist that acts on the GLP-1 receptor, the GIP receptor, and the glucagon receptor, and the glucagon arm is the one that...
The short version is this: retatrutide acts at the GLP-1 receptor, but it is not a GLP-3, because there is no such thing as a GLP-3. The most accurate label for the molecule is a triple receptor agonist, since it activates the GLP-1 receptor along with the GIP...
Retatrutide, the peptide assigned the development code LY3437943, works through one mechanism that acts in three places at once. It is a triple receptor agonist, which means a single molecule binds to and activates three separate G-protein-coupled receptors: the GLP-1...
Status checked July 24, 2026. Review retatrutide’s U.S. investigational status, RUO limits, compounding restrictions, marketing, import, and research rules.
Retatrutide, or LY3437943, is an investigational GIPR/GLP-1R/GCGR triple agonist. This research-only overview explains its nomenclature, receptor profile, evidence timeline, current status, and analytical-documentation requirements.
A source-led overview of retatrutide receptor pharmacology, phase 2 evidence, ongoing clinical research, and laboratory study considerations.
Understand what filler-free means, what HPLC and mass spectrometry can show, and how to evaluate a lot-specific COA without conflating purity, identity, and content.
Join our list and get an instant discount code.
Use this code at checkout: